Hereditary Angioedema Therapeutics Market - Global Forecast 2026-2032

The Hereditary Angioedema Therapeutics Market is projected to reach USD 5.28 Billion in 2026. It is expected to continue growing at a CAGR of 5.53%, reaching USD 7.31 Billion by 2032.

Hereditary angioedema therapeutics are moving from episodic emergency intervention toward personalized, prevention-led disease control across on-demand treatment, short-term prophylaxis, and long-term prophylaxis. HAE is a rare, autosomal dominant, bradykinin-mediated disorder most often linked to quantitative or functional C1 esterase inhibitor deficiency, causing recurrent swelling of the skin, gastrointestinal tract, and airway; laryngeal involvement remains a critical safety concern. Current treatment strategies focus on rapid attack resolution, reduction of attack frequency, patient self-administration, and quality-of-life improvement through C1-INH replacement, bradykinin B2 receptor antagonism, plasma kallikrein inhibition, factor XIIa inhibition, and RNA-targeted approaches.

Transformative Shifts in the Hereditary Angioedema Treatment Landscape

The hereditary angioedema therapeutics landscape is being reshaped by three interlocking shifts: earlier self-administration, broader prophylaxis choices, and new molecular targets within the kallikrein-kinin pathway. International guidance recommends that all patients have on-demand therapy and that long-term prophylaxis be individualized based on disease activity, quality of life, treatment burden, patient preference, and health-resource availability; first-line prophylaxis has historically included plasma-derived C1-INH, lanadelumab, and berotralstat. Since 2025, regulatory decisions have added important modalities, including an oral plasma kallikrein inhibitor for acute attacks, a factor XIIa inhibitor for prevention, and a prekallikrein-directed antisense oligonucleotide for prevention, expanding clinical decision-making from route-of-administration convenience to mechanism-based sequencing and breakthrough-attack management.

Cumulative Impact of Artificial Intelligence on HAE Therapeutics

Artificial intelligence is beginning to affect hereditary angioedema therapeutics less as a stand-alone therapy and more as an enabling layer across diagnosis, trial design, real-world evidence, and patient support. HAE is frequently confused with allergy, gastrointestinal disease, or nonspecific swelling, and studies using electronic medical records show that structured and unstructured clinical data can be leveraged to proactively identify rare-disease patients who may otherwise remain undiagnosed. In Japan-focused algorithm development, researchers highlighted the difficulty of machine learning in HAE because positive training datasets are small, yet the work demonstrates how symptom patterns such as recurrent abdominal pain and edema can support earlier suspicion. Quantitative systems pharmacology models of the kallikrein-kinin pathway also create a data-driven foundation for simulating bradykinin dynamics, treatment adherence, pharmacokinetics, and prophylaxis selection, while responsible AI governance remains essential for bias control, explainability, privacy, and validation across ethnic and health-system contexts.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

In Asia-Pacific, hereditary angioedema therapeutics are advancing through Japan and Australia’s more established regulatory pathways while China, India, South Korea, and several Southeast Asian systems continue to prioritize diagnostic capacity, specialist awareness, and equitable access. Asia-Pacific studies report that many countries still lack consistent access to diagnostic testing and evidence-based therapies, with resource-constrained guidance from the Indian subcontinent emphasizing that intravenous plasma-derived C1-INH may be the only available first-line option in some settings. North America remains a high-evidence, guideline-driven environment, with U.S. regulatory approvals in 2025 for new prophylactic and on-demand mechanisms and Canadian guidance emphasizing comprehensive care, individualized prophylaxis, and immediate access to attack therapy. Latin America is characterized by active clinical expertise in Brazil and Mexico but persistent access and diagnosis gaps; Brazilian guidance supports crisis treatment with icatibant or plasma-derived C1 inhibitor, while Mexico-focused real-world literature documents long diagnostic delays and uneven access to specialized care. Europe benefits from centralized EU authorization, national reference networks, and recent approvals for factor XIIa inhibition, oral on-demand plasma kallikrein inhibition, and RNA-targeted prophylaxis, while country-level reimbursement remains the key determinant of treatment availability. The Middle East has developed regional Delphi consensus recommendations because implementation of global HAE guidance requires adaptation to heterogeneous awareness, diagnostic access, and self-administration infrastructure. Africa remains the most access-constrained region in the evidence base, with South African data showing that limited on-demand therapy availability and cost concerns are linked to worse disease control and quality-of-life outcomes, making emergency-treatment readiness and specialist referral pathways central priorities.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7 & NATO

Across ASEAN, hereditary angioedema therapeutics are shaped by uneven diagnostic infrastructure, variable access to C4, C1-INH level, C1-INH functional testing, and limited specialist density, making regional education, referral algorithms, and affordable on-demand treatment availability more important than broad formulary breadth. In the GCC, the Middle East Delphi consensus points to the value of harmonized specialist education, patient self-administration training, and regional adaptation of global guidance across Gulf health systems. The European Union provides a strong regulatory convergence model through centralized medicines assessment and orphan-medicine pathways, enabling multi-country authorization for recent HAE therapies while leaving reimbursement and patient access to national decision-making. BRICS countries combine advanced clinical centers with significant access heterogeneity: Brazil has national guidance, Russia has emerging regional experience with modern prophylaxis, India has resource-constrained consensus guidance, China has updated expert consensus and expanding awareness initiatives, and South Africa illustrates the quality-of-life impact of restricted on-demand access. The G7 group concentrates several of the most mature HAE care environments, including the United States, Canada, the United Kingdom, Germany, France, Italy, and Japan, where regulatory approvals, clinical trial participation, and specialist centers support evidence generation and therapy uptake. NATO should be viewed as a continuity-of-care and emergency-readiness lens rather than a medicines payer; because many NATO members overlap with G7 and EU systems, manufacturers and care networks should prioritize cross-border documentation, travel-ready rescue plans, and alignment with nationally approved on-demand options for mobile populations.

Key Country Insights Across Major HAE Therapeutics Markets

In the United States, 2025 marked a major therapeutic expansion as regulators cleared new HAE options spanning factor XIIa inhibition, oral on-demand kallikrein inhibition, and RNA-targeted prophylaxis for patients aged 12 years and older where indicated. Canada is reinforcing guideline-based management through updated international and Canadian recommendations and authorization of factor XIIa inhibition for routine prevention in patients 12 years and older. Mexico shows a high unmet-need profile, with real-world research describing long diagnostic delays and pediatric literature calling out underdiagnosis and inequitable access to specialized therapies. Brazil has one of Latin America’s strongest documented HAE guidance bases, with recommendations supporting C1-INH and bradykinin B2 receptor antagonist use for acute crises while access pathways continue to shape real-world treatment. In the United Kingdom, recent approvals for oral on-demand treatment and RNA-targeted prophylaxis, alongside commissioned treatment algorithms, support a more structured rare-immunology pathway. Germany, France, Italy, and Spain operate within the EU authorization framework and benefit from specialist reference centers, but Spain-specific patient-journey research still identifies training, early diagnosis, and high-cost therapy access as continuing issues. Russia’s recent regional experience with modern prophylaxis indicates growing clinical adoption in specialist settings, although availability remains location-dependent. China’s updated expert consensus and Greater Bay Area access initiatives show a shift from awareness-building toward structured diagnosis and treatment alignment. India’s consensus for resource-constrained settings emphasizes pragmatic diagnosis and C1-INH-based management where modern options are limited. Japan has progressively broadened approved HAE options, with official review documents listing icatibant, intravenous C1-inactivator therapy, berotralstat, lanadelumab, and garadacimab among approved medicines. Australia has accelerated access with 2025 approval of garadacimab for routine prevention and approval of sebetralstat for attacks in patients aged 12 years and older. South Korea sits within the wider Asia-Pacific access pattern, where specialist awareness is improving but country-specific reimbursement and diagnostic standardization remain decisive for patient-level uptake.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize diagnosis-to-treatment integration rather than isolated product positioning. The most actionable pathway is to support specialist referral triggers in allergy, emergency medicine, gastroenterology, pediatrics, dermatology, and primary care; ensure every diagnosed patient has a written action plan and access to effective on-demand treatment; and design education around the difference between bradykinin-mediated HAE and histamine-mediated angioedema. Portfolio strategy should address both acute and preventive needs because breakthrough attacks can persist even in patients receiving long-term prophylaxis, and treatment burden remains tied to route of administration, portability, training, and payer authorization. Leaders should also build real-world evidence programs that track attack frequency, time to treatment, rescue-medication use, patient-reported outcomes, quality of life, adherence, and reasons for delayed treatment, while tailoring access programs for regions where C1-INH testing, functional assays, genetic confirmation, and specialist centers are limited.

Research Methodology

This executive summary applies a verified, evidence-led methodology using peer-reviewed clinical guidelines, systematic reviews, regulatory drug snapshots, national treatment guidance, regional consensus statements, and real-world patient or physician surveys. The analysis excludes market sizing, share estimation, and forecasting, and instead focuses on clinical need, treatment mechanisms, regulatory milestones, access barriers, diagnostic pathways, and regional readiness. Source prioritization favored official regulators, open-access clinical journals, indexed biomedical databases, and consensus guidance; findings were cross-checked across disease epidemiology, treatment standards, and regulatory updates to maintain recency and reduce interpretation bias. Country and group insights were synthesized narratively to preserve for hereditary angioedema therapeutics, C1 inhibitor deficiency, kallikrein inhibitors, bradykinin-mediated angioedema, HAE prophylaxis, oral on-demand HAE therapy, and rare disease treatment access.

Conclusion

Hereditary angioedema therapeutics have entered a new phase defined by patient-centered control, mechanism diversity, and faster self-administered care. The strongest opportunities lie in shortening the diagnostic odyssey, improving availability of validated C4 and C1-INH testing, expanding specialist education, ensuring immediate access to on-demand therapy, and matching prophylaxis decisions to patient burden and treatment goals. Recent approvals across the United States, Europe, the United Kingdom, Australia, Canada, and Japan demonstrate accelerating innovation, while evidence from Asia-Pacific, Latin America, the Middle East, and Africa shows that therapeutic progress must be paired with practical access infrastructure. Leaders that connect science, evidence generation, digital enablement, and equitable care pathways will be best positioned to improve outcomes in this rare, unpredictable, and potentially life-threatening condition.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.1.1. Convenience Shift
4.3.1.2. Mechanism Innovation
4.3.1.3. Pediatric and Diagnosis Expansion
4.3.2. Key Restraints
4.3.2.1. Cost Pressure
4.3.2.2. Clinician Inertia
4.3.2.3. Long Term Safety Uncertainty
4.3.3. Key Opportunities
4.3.3.1. Oral Rescue Adoption
4.3.3.2. Long Interval Prophylaxis
4.3.3.3. Disease Modifying Therapy
4.3.4. Key Challenges
4.3.4.1. Access Controls
4.3.4.2. Patient Identification
4.3.4.3. Differentiation Burden
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hereditary Angioedema Therapeutics Market, by Treatment Intent

7.1. Introduction
7.2. Acute Attack Treatment
7.3. Long-Term Prophylaxis
7.4. Short-Term Prophylaxis

8. Hereditary Angioedema Therapeutics Market, by Therapeutic Class

8.1. Introduction
8.2. Bradykinin B2 Receptor Antagonists
8.3. Plasma Kallikrein Inhibitors
8.4. Attenuated Androgens
8.5. C1 Esterase Inhibitors
8.6. Factor XIIa Inhibitors
8.7. Prekallikrein Gene Silencers
8.8. Antifibrinolytics

9. Hereditary Angioedema Therapeutics Market, by Administration Route

9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous

10. Hereditary Angioedema Therapeutics Market, by Molecule Modality

10.1. Introduction
10.2. Plasma Derived Proteins
10.3. Recombinant Proteins
10.4. Small Molecules
10.5. Monoclonal Antibodies
10.6. RNA Targeted Medicines
10.7. Gene Editing Medicines

11. Hereditary Angioedema Therapeutics Market, by Care Setting

11.1. Introduction
11.2. Specialty Clinics
11.3. Home Care
11.4. Hospitals and Emergency Departments
11.5. Ambulatory Infusion Centers

12. Hereditary Angioedema Therapeutics Market, by Dispensing Channel

12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
12.5. Specialty Pharmacies
12.6. Manufacturer Patient Support Hubs

13. Hereditary Angioedema Therapeutics Market, by Disease Subtype

13.1. Introduction
13.2. HAE Type I
13.3. HAE Type II
13.4. HAE with Normal C1 Inhibitor

14. Hereditary Angioedema Therapeutics Market, by Age Eligibility

14.1. Introduction
14.2. Adults
14.3. Adolescents
14.4. Children
14.5. Infants and Toddlers

15. Hereditary Angioedema Therapeutics Market, by Lifecycle Stage

15.1. Introduction
15.2. Approved Branded Therapies
15.3. Approved Generics
15.4. Registration Stage Therapies
15.5. Late Stage Clinical Therapies
15.6. Early Stage Clinical Therapies

16. Hereditary Angioedema Therapeutics Market, by Region

16.1. North America
16.2. Europe
16.3. Asia-Pacific
16.4. Latin America
16.5. Middle East
16.6. Africa

17. Hereditary Angioedema Therapeutics Market, by Group

17.1. NATO
17.2. G7
17.3. European Union
17.4. BRICS
17.5. GCC
17.6. ASEAN

18. Hereditary Angioedema Therapeutics Market, by Country

18.1. United States
18.2. China
18.3. Germany
18.4. Canada
18.5. Japan
18.6. United Kingdom
18.7. Brazil
18.8. Mexico
18.9. France
18.10. India
18.11. Australia
18.12. Italy
18.13. Russia
18.14. South Korea
18.15. Spain

19. Competitive Landscape

19.1. Market Share Analysis, 2025
19.2. FPNV Positioning Matrix, 2025
19.3. Market Concentration Analysis, 2025
19.3.1. Concentration Ratio (CR)
19.3.2. Herfindahl Hirschman Index (HHI)
19.4. Recent Developments & Impact Analysis, 2025
19.5. Product Portfolio Analysis, 2025
19.6. Benchmarking Analysis, 2025

20. Company Profiles

20.1. Takeda Pharmaceutical Company Limited
20.2. CSL Limited
20.3. BioCryst Pharmaceuticals, Inc.
20.4. Pharming Group N.V.
20.5. Others
20.6. KalVista Pharmaceuticals, Inc.
20.7. Neopharmed Gentili S.p.A.
20.8. Teva Pharmaceutical Industries Ltd.
20.9. Fresenius Kabi AG
20.10. Cipla Limited
20.11. Cycle Pharmaceuticals Limited
20.12. Alembic Pharmaceuticals Limited
20.13. Sandoz Group AG
20.14. Sun Pharmaceutical Industries Limited
20.15. Apotex Inc.
20.16. Glenmark Pharmaceuticals Limited
20.17. Lupin Limited
20.18. GENESIS Pharma S.A.
20.19. Swixx Biopharma AG
20.20. Intellia Therapeutics, Inc.
20.21. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
20.22. Kaken Pharmaceutical Co., Ltd.
20.23. Otsuka Pharmaceutical Co., Ltd.
20.24. Pharvaris N.V.

List of Figures

FIGURE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 27. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 29. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 31. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ACUTE ATTACK TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ACUTE ATTACK TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ACUTE ATTACK TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL LONG-TERM PROPHYLAXIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL LONG-TERM PROPHYLAXIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL LONG-TERM PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SHORT-TERM PROPHYLAXIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SHORT-TERM PROPHYLAXIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SHORT-TERM PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL BRADYKININ B2 RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL BRADYKININ B2 RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL BRADYKININ B2 RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PLASMA KALLIKREIN INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PLASMA KALLIKREIN INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PLASMA KALLIKREIN INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ATTENUATED ANDROGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ATTENUATED ANDROGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ATTENUATED ANDROGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL C1 ESTERASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL C1 ESTERASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL C1 ESTERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL FACTOR XIIA INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL FACTOR XIIA INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL FACTOR XIIA INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PREKALLIKREIN GENE SILENCERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PREKALLIKREIN GENE SILENCERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PREKALLIKREIN GENE SILENCERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ANTIFIBRINOLYTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ANTIFIBRINOLYTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ANTIFIBRINOLYTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PLASMA DERIVED PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PLASMA DERIVED PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PLASMA DERIVED PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL RNA TARGETED MEDICINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL RNA TARGETED MEDICINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL RNA TARGETED MEDICINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL GENE EDITING MEDICINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL GENE EDITING MEDICINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL GENE EDITING MEDICINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS AND EMERGENCY DEPARTMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITALS AND EMERGENCY DEPARTMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL HOSPITALS AND EMERGENCY DEPARTMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL AMBULATORY INFUSION CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL AMBULATORY INFUSION CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL AMBULATORY INFUSION CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL MANUFACTURER PATIENT SUPPORT HUBS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL MANUFACTURER PATIENT SUPPORT HUBS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL MANUFACTURER PATIENT SUPPORT HUBS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL HAE TYPE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HAE TYPE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HAE TYPE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HAE TYPE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HAE TYPE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HAE TYPE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL HAE WITH NORMAL C1 INHIBITOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL HAE WITH NORMAL C1 INHIBITOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL HAE WITH NORMAL C1 INHIBITOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ADULTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL ADOLESCENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL ADOLESCENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ADOLESCENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL CHILDREN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL CHILDREN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL CHILDREN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL INFANTS AND TODDLERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL INFANTS AND TODDLERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL INFANTS AND TODDLERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL APPROVED BRANDED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL APPROVED BRANDED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL APPROVED BRANDED THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL APPROVED GENERICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL APPROVED GENERICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL APPROVED GENERICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL REGISTRATION STAGE THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL REGISTRATION STAGE THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL REGISTRATION STAGE THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL LATE STAGE CLINICAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL LATE STAGE CLINICAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL LATE STAGE CLINICAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL EARLY STAGE CLINICAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL EARLY STAGE CLINICAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL EARLY STAGE CLINICAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 143. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 145. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 146. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 147. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 148. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 149. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 151. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 152. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 183. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 184. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 185. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 186. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 187. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 188. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 189. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 191. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 192. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 193. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 194. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 195. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 196. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 197. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 198. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 199. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 200. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 201. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 202. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 203. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 204. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 205. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 206. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 207. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 208. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 209. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 210. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 211. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 212. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 213. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 224. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 225. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 226. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 227. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 228. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 229. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 230. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 232. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 233. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 234. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 235. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 236. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 237. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 238. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 239. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 240. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 241. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 242. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 243. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 244. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 245. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 246. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 247. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 248. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 249. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 250. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 251. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 252. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 253. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 254. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 255. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 257. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 258. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 259. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 260. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 261. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 262. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 263. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 264. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 265. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 267. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 268. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 269. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 270. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 271. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 272. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 273. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 274. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 275. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 276. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 277. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 278. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 279. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 280. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 281. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 282. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 283. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 284. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 285. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 286. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 287. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 288. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 289. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 290. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 291. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 292. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 293. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 294. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 295. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 297. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 298. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 299. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 300. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 301. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 302. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 303. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 304. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 305. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 306. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 307. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 308. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 309. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 310. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 311. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 312. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE SUBTYPE, 2017-2032 (USD MILLION)
TABLE 313. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY AGE ELIGIBILITY, 2017-2032 (USD MILLION)
TABLE 314. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY LIFECYCLE STAGE, 2017-2032 (USD MILLION)
TABLE 315. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT INTENT, 2017-2032 (USD MILLION)
TABLE 317. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 318. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 319. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2017-2032 (USD MILLION)
TABLE 320. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 321. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISPENSING CHANNEL, 2017-2032 (USD MILLION)
TABLE 322. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISEASE S

Companies Mentioned

Takeda Pharmaceutical Company Limited
CSL Limited
BioCryst Pharmaceuticals, Inc.
Pharming Group N.V.
Others
KalVista Pharmaceuticals, Inc.
Neopharmed Gentili S.p.A.
Teva Pharmaceutical Industries Ltd.
Fresenius Kabi AG
Cipla Limited
Cycle Pharmaceuticals Limited
Alembic Pharmaceuticals Limited
Sandoz Group AG
Sun Pharmaceutical Industries Limited
Apotex Inc.
Glenmark Pharmaceuticals Limited
Lupin Limited
GENESIS Pharma S.A.
Swixx Biopharma AG
Intellia Therapeutics, Inc.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Kaken Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Pharvaris N.V.

Table Information

Report Attribute	Details
No. of Pages	184
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 5.28 Billion
Forecasted Market Value ( USD ) by 2032	$ 7.31 Billion
Compound Annual Growth Rate	5.5%
Regions Covered	Global
No. of Companies Mentioned	24

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3137EUR$3,545USD£2,688GBP €3485EUR$3,939USD£2,987GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4745EUR$5,363USD£4,066GBP €5273EUR$5,959USD£4,518GBP

Transformative Shifts in the Hereditary Angioedema Treatment Landscape

Cumulative Impact of Artificial Intelligence on HAE Therapeutics

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7 & NATO

Key Country Insights Across Major HAE Therapeutics Markets

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Hereditary Angioedema Therapeutic Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Angioedema Treatment Market - Global Forecast 2026-2032

Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Hereditary Angioedema Therapeutics Market Report 2026

Hereditary Angioedema Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type